ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) - Cummin, T.E.; Caddy, J.; Mercer, K.; Maishman, T.; Schuh, A.; Lopez Pascua, L.; Collins, G.; McMillan, A.; Ardeshna, K.; Galanopoulous, A.; Burton, C.; Barrans, S.; et al.